Jpmorgan Chase & CO Verve Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.1 Trillion
- Q1 2024
A detailed history of Jpmorgan Chase & CO transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,493,050 shares of VERV stock, worth $7.75 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,493,050
Previous 2,058,399
27.47%
Holding current value
$7.75 Million
Previous $28.7 Million
30.9%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding VERV
# of Institutions
169Shares Held
78.3MCall Options Held
125KPut Options Held
185K-
Alphabet Inc. Mountain View, CA12.3MShares$64.1 Million7.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.33MShares$32.9 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl6.04MShares$31.4 Million0.57% of portfolio
-
Black Rock Inc. New York, NY5.37MShares$27.9 Million0.0% of portfolio
-
State Street Corp Boston, MA5.1MShares$26.5 Million0.0% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $311M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...